Optimizing care for low-grade serous ovarian carcinoma: insights from a tertiary care centre
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20263043Keywords:
Cytoreductive surgery, Chemotherapy resistance, Low-grade serous ovarian carcinoma, Neoadjuvant chemotherapy, Ovarian cancer, Overall survivalAbstract
Background: Low-grade serous ovarian carcinoma (LGSC) is an uncommon epithelial ovarian malignancy with distinct tumour biology, relatively indolent behaviour, frequent advanced-stage presentation and limited sensitivity to conventional chemotherapy. This study evaluated the clinicopathological profile, treatment pattern, perioperative outcomes and survival of patients with LGSC managed at a tertiary cancer centre.
Methods: A retrospective review was conducted of 23 patients with histologically confirmed LGSC treated between 2014 and 2025. Demographic characteristics, clinical presentation, tumour markers, FIGO stage, disease distribution, chemotherapy response, surgical approach, completeness of cytoreduction, postoperative morbidity, recurrence and survival outcomes were analyzed descriptively.
Results: The median age was 47 years. Abdominal pain was the most common presenting symptom, reported in 17 patients (73.91%). Serum CA-125 was elevated in 19 patients (82.6%), with a median value of 89 U/ml. FIGO stage III disease was present in 18 patients (78.26%). Nine patients received neoadjuvant chemotherapy; objective response was observed in only 2 patients (22.2%), while 5 had stable disease and 2 progressed. Primary cytoreductive surgery was performed in 12 patients, interval cytoreduction in 9 and staging laparotomy in 2. Complete cytoreduction was achieved in 19 patients (82.6%). Grade III morbidity occurred in 21.7%, with no Grade IV/V complications or 30-day mortality. At 36-month median follow-up, recurrence occurred in 6 patients; 3 years overall survival was 75% and disease-free survival was 66%.
Conclusions: LGSC commonly presents with advanced peritoneal disease and poor chemotherapy response. Complete cytoreduction remains the key therapeutic goal.
References
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023;33(9):1331-44.
WHO classification of tumours editorial board. female genital tumours. 5th ed. Vol. 4. Lyon: international agency for research on cancer; 2020. Available at: https://tumourclassification.iarc.who.int. Accessed on 21 January 2026.
Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget. 2015;6(35):37663-77.
Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484-6.
Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143(2):433-8.
Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer: an analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140(3):457-62.
Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, et al. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011;120(2):229-32.
Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108(3):510-4.
Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114(1):48-52.
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(28):3460-73.
Fader AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, Roche KL, Stone RL, et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival. Gynecol Oncol. 2017;147(1):85-91.
Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015;136(1):25-9.
Dash B, Shylasree TS, Rekhi B, Gulia S, Ghosh J, Maheshwari A, et al. Clinical observations and outcomes in advanced low-grade serous carcinoma of the ovary: case series from a tertiary cancer center. Indian J Surg Oncol. 2023;14(4):784-92.
Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134-40.
Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-53.
Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol. 2017;35(10):1103-11.
Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, et al. Efficacy and safety of avutometinib +/- defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025;43(25):2782-92.
Downloads
Published
How to Cite
Issue
Section
